Equities

Assertio Holdings Inc

ASRT:NAQ

Assertio Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.35
  • Today's Change0.05 / 3.85%
  • Shares traded517.77k
  • 1 Year change-49.06%
  • Beta0.7860
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments736537
Total Receivables, Net484544
Total Inventory38147.49
Prepaid expenses128.2715
Other current assets, total0.30----
Total current assets171132103
Property, plant & equipment, net2.040.882.26
Goodwill, net------
Intangibles, net111198216
Long term investments--0.271.58
Note receivable - long term------
Other long term assets0.700.700.70
Total assets286414327
LIABILITIES
Accounts payable135.996.69
Accrued expenses776269
Notes payable/short-term debt000
Current portion long-term debt/capital leases00.4712
Other current liabilities, total2.732747
Total current liabilities9395135
Total long term debt396661
Total debt396773
Deferred income tax------
Minority interest------
Other liabilities, total162628
Total liabilities148188224
SHAREHOLDERS EQUITY
Common stock0.010.010.00
Additional paid-in capital790545532
Retained earnings (accumulated deficit)(652)(320)(429)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity138226102
Total liabilities & shareholders' equity286414327
Total common shares outstanding954845
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.